{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:50:42Z","timestamp":1790265042269,"version":"4.1.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"DOI":"10.1093\/ndt\/gfw361","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T19:08:00Z","timestamp":1486062480000},"page":"i80-i88","source":"Crossref","is-referenced-by-count":25,"title":["Is there a role for TNF\u03b1 blockade in ANCA-associated vasculitis and glomerulonephritis?"],"prefix":"10.1093","volume":"32","author":[{"given":"Stephen P","family":"McAdoo","sequence":"first","affiliation":[{"name":"Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D","family":"Pusey","sequence":"additional","affiliation":[{"name":"Renal and Vascular Inflammation Section, Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"key\n\t\t\t\t20180315025508_gfw361C1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1681\/ASN.2005121359","article-title":"Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases","volume":"17","author":"Feldmann","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000342333","article-title":"Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases","volume":"36","author":"Speeckaert","year":"2012","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semnephrol.2007.02.004","article-title":"Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation","volume":"27","author":"Vielhauer","year":"2007","journal-title":"Semin Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C4","doi-asserted-by":"crossref","first-page":"493593","DOI":"10.1155\/2014\/493593","article-title":"Anti-TNF-alpha therapy and systemic vasculitis","volume":"2014","author":"Jarrot","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"Suppl 4","key":"key\n\t\t\t\t20180315025508_gfw361C5","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1136\/ard.2005.042416","article-title":"Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis","volume":"64","author":"Mukhtyar","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180315025508_gfw361C6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2249.1990.tb03336.x","article-title":"Enhanced expression of the tumour necrosis factor\/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis","volume":"81","author":"Deguchi","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","article-title":"In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis","volume":"43","author":"Noronha","year":"1993","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180315025508_gfw361C8","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0002-9440(10)61118-2","article-title":"Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis","volume":"160","author":"Komocsi","year":"2002","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2249.1994.tb06518.x","article-title":"Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo","volume":"95","author":"Csernok","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20180315025508_gfw361C11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1084\/jem.177.5.1277","article-title":"Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55","volume":"177","author":"Mackay","year":"1993","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20180315025508_gfw361C12","doi-asserted-by":"crossref","first-page":"c222","DOI":"10.1159\/000235242","article-title":"Expression of tumor necrosis factor receptors on granulocytes in patients with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis","volume":"113","author":"Hasegawa","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"key\n\t\t\t\t20180315025508_gfw361C13","doi-asserted-by":"crossref","first-page":"e0122212","DOI":"10.1371\/journal.pone.0122212","article-title":"Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy","volume":"10","author":"Sonoda","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180315025508_gfw361C14","doi-asserted-by":"crossref","first-page":"e104354","DOI":"10.1371\/journal.pone.0104354","article-title":"Circulating TNF receptors are significant prognostic biomarkers for idiopathic membranous nephropathy","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180315025508_gfw361C15","doi-asserted-by":"crossref","first-page":"e68167","DOI":"10.1371\/journal.pone.0068167","article-title":"Distinct contributions of TNF receptor 1 and 2 to TNF-induced glomerular inflammation in mice","volume":"8","author":"Taubitz","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180315025508_gfw361C16","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.4049\/jimmunol.142.9.3083","article-title":"Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1","volume":"142","author":"Tomosugi","year":"1989","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C17","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/ki.1995.472","article-title":"Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor","volume":"48","author":"Karkar","year":"1995","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180315025508_gfw361C18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/BF03401805","article-title":"TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis","volume":"3","author":"Lan","year":"1997","journal-title":"Mol Med"},{"key":"key\n\t\t\t\t20180315025508_gfw361C19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ndt\/16.3.518","article-title":"Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha","volume":"16","author":"Karkar","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180315025508_gfw361C20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1523-1755.2005.00279.x","article-title":"Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis","volume":"67","author":"Khan","year":"2005","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180315025508_gfw361C21","first-page":"1625","article-title":"Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice","volume":"78","author":"Le Hir","year":"1998","journal-title":"Lab Invest"},{"key":"key\n\t\t\t\t20180315025508_gfw361C22","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1097\/01.ASN.0000073902.38428.33","article-title":"Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis","volume":"14","author":"Timoshanko","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2005060616","article-title":"Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis","volume":"17","author":"Little","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0002-9440(10)62952-5","article-title":"Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha","volume":"167","author":"Huugen","year":"2005","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2004-01-0267","article-title":"Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo","volume":"104","author":"Pfister","year":"2004","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180315025508_gfw361C26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/331356a0","article-title":"Tumour necrosis factor-alpha in murine autoimmune \u2018lupus\u2019 nephritis","volume":"331","author":"Jacob","year":"1988","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180315025508_gfw361C27","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.4049\/jimmunol.143.11.3470","article-title":"Tumor necrosis factor and IL-1 in New Zealand Black\/White mice. Enhanced gene expression and acceleration of renal injury","volume":"143","author":"Brennan","year":"1989","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ki.1995.14","article-title":"Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms","volume":"47","author":"Yokoyama","year":"1995","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180315025508_gfw361C29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1191\/096120301675275538","article-title":"Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline","volume":"10","author":"Segal","year":"2001","journal-title":"Lupus"},{"key":"key\n\t\t\t\t20180315025508_gfw361C30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180315025508_gfw361C31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","article-title":"Safety and efficacy of TNFalpha blockade in relapsing vasculitis","volume":"61","author":"Booth","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180315025508_gfw361C32","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180315025508_gfw361C33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180315025508_gfw361C34","first-page":"85","article-title":"Crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil-cytoplasmic antibodies: first report on the efficacy of primary anti-TNF-alpha treatment","volume":"26","author":"Zaenker","year":"2004","journal-title":"Int J Tissue React"},{"key":"key\n\t\t\t\t20180315025508_gfw361C35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03040906","article-title":"Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade","volume":"116","author":"Kleinert","year":"2004","journal-title":"Wien Klin Wochenschr"},{"key":"key\n\t\t\t\t20180315025508_gfw361C36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315025508_gfw361C38","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.30394","article-title":"Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort","volume":"63","author":"Silva","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180315025508_gfw361C39","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/ard.2007.083584","article-title":"Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients","volume":"67","author":"Josselin","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180315025508_gfw361C40","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/ndt\/gfq187","article-title":"Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement","volume":"25","author":"Laurino","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180315025508_gfw361C41","doi-asserted-by":"crossref","first-page":"c89","DOI":"10.1159\/000319655","article-title":"Addition of infliximab to standard therapy for ANCA-associated vasculitis","volume":"117","author":"Morgan","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"(1 Suppl 64)","key":"key\n\t\t\t\t20180315025508_gfw361C42","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C43","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.0000124720.18538.DD","article-title":"Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation","volume":"109","author":"Booth","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180315025508_gfw361C44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180315025508_gfw361C45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20180315025508_gfw361C46","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180315025508_gfw361C47","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"J Am Med Assoc"},{"key":"key\n\t\t\t\t20180315025508_gfw361C48","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10792-015-0124-0","article-title":"Biologic therapy for refractory scleritis: a new treatment perspective","volume":"35","author":"de Fidelix","year":"2015","journal-title":"Int Ophthalmol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000271","article-title":"Retinal vasculitis","volume":"28","author":"Rosenbaum","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2011.05.001","article-title":"Therapeutic blockade of TNF in patients with SLE-promising or crazy?","volume":"11","author":"Aringer","year":"2012","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t20180315025508_gfw361C51","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180315025508_gfw361C52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0961203309102557","article-title":"Efficacy and safety of infliximab in active SLE: a pilot study","volume":"18","author":"Uppal","year":"2009","journal-title":"Lupus"},{"key":"key\n\t\t\t\t20180315025508_gfw361C53","first-page":"416","article-title":"Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients","volume":"27","author":"Matsumura","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0272-6386(12)80742-6","article-title":"Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans","volume":"21","author":"Suranyi","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180315025508_gfw361C55","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00467-003-1122-4","article-title":"Tumor necrosis factor-alpha production from mononuclear cells in nephrotic syndrome","volume":"18","author":"Bakr","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C56","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1600-6143.2009.02550.x","article-title":"Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis","volume":"9","author":"Leroy","year":"2009","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180315025508_gfw361C57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2369-11-2","article-title":"Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group","volume":"11","author":"Peyser","year":"2010","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-015-0094-5","article-title":"Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group","volume":"16","author":"Trachtman","year":"2015","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/1744666X.4.2.275","article-title":"Autoantibody production in patients treated with anti-TNF-alpha","volume":"4","author":"Atzeni","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t20180315025508_gfw361C61","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180315025508_gfw361C62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C63","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t20180315025508_gfw361C64","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180315025508_gfw361C65","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5414\/CNP62234","article-title":"Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis","volume":"62","author":"Doulton","year":"2004","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20180315025508_gfw361C66","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl JMed"},{"key":"key\n\t\t\t\t20180315025508_gfw361C67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/thx.2010.144295","article-title":"Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease","volume":"65","author":"British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee","year":"2010","journal-title":"Thorax"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/32\/suppl_1\/i80\/24363762\/gfw361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:25:47Z","timestamp":1749943547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/suppl_1\/i80\/2930800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":67,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2017,1,20]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw361","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2017,1,1]]}}}